What diseases is ivonib mainly used to treat? Which patient groups is it suitable for?

Ivosidenib is a targeted drug mainly used to treat acute myeloid leukemia (AML), especially those patients with IDH1 gene mutations. IDH1 (isocitrate dehydrogenase 1) gene mutation is a common genetic change in some types of leukemia. Avosidenib helps inhibit the growth and proliferation of cancer cells by specifically inhibiting the effect of the IDH1 mutation product.

Ivosidenib (Ivosidenib) is approved to treat acute myeloid leukemia (AML), specifically those with mutations in the IDH1 gene. IDH1 Gene mutations can cause abnormalities in certain metabolic pathways in leukemia cells, prompting leukemia cells to proliferate and inhibiting their normal differentiation. As an IDH1 inhibitor, ivonib can reverse the abnormal metabolism caused by this mutation and promote the normal differentiation process of leukemia cells, thereby inhibiting tumor growth.

Avosidenib is suitable for patients with IDH1 mutation-positive acute myeloid leukemia, especially those who are not suitable for chemotherapy or have experienced failure to respond to other treatments. These patients may not be able to tolerate the severe side effects of traditional chemotherapy drugs, and ivonib provides them with a targeted therapy option. Ivonib is an oral medication that patients can take conveniently at home without the need for frequent hospitalization.

In addition, ivonib is also suitable for those AML patients who have failed traditional treatments due to disease progression or drug resistance, especially those young patients or elderly patients who are often unable to tolerate traditional chemotherapy due to their weak body.

Avosidenib is a drug that targets IDH1 gene mutations and is mainly used to treat acute myeloid leukemia, especially those patients with IDH1 mutations. It provides a new treatment option with significant therapeutic value, especially for patients who cannot tolerate traditional chemotherapy.

Reference link:https://www.tibsovo.com/